Today, on World Arthritis Day 2024, we shine a light on Osteoarthritis (OA), a disease that affects more than 500 million people across Europe. Osteoarthritis, particularly in the knee, significantly impacts quality of life, causing pain, reduced mobility, and loss of independence. While current therapies offer moderate efficacy, they are often associated with long-term side effects, leaving many patients without effective long-term solutions.
At Asphalion, we are proud to contribute to the EU-funded siNPAIN project, which aims to address this critical healthcare challenge. The goal of siNPAIN is to transform the way OA is treated by developing a new generation of therapeutics. These innovative therapies are based on siRNA nanotechnology, designed to target and treat the different stages of knee osteoarthritis more effectively and safely.
The international team behind the SINPAIN project envisions treatments that will not only alleviate pain for millions of patients but also reduce the substantial healthcare costs associated with long-term management of OA. By focusing on nanotherapeutics, the project seeks to offer a more precise and targeted approach to treatment, minimizing side effects and maximizing relief for patients.
This ambitious project represents a step forward in OA treatment, with the potential to improve quality of life for people worldwide, particularly for those suffering from the pain and limitations of knee osteoarthritis.
Asphalion is committed to advancing healthcare innovation, and we are excited to be part of this international collaboration that is pushing the boundaries of what’s possible in osteoarthritis treatment.
Together, we aim to make a real impact on OA treatment and bring much-needed relief to millions.
Learn more about the siNPAIN project and join us in supporting the fight against osteoarthritis on this World Arthritis Day.
Contact us for further information: [email protected]
